Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;5(4):391-392.
doi: 10.1016/j.jshs.2016.08.009. Epub 2016 Aug 24.

Mechanism of neurodegeneration through tau and therapy for Alzheimer's disease

Akihiko Takashima  1
Affiliations

Mechanism of neurodegeneration through tau and therapy for Alzheimer's disease

Akihiko Takashima. J Sport Health Sci. 2016 Dec.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Before neurofibrillary tangle (NFT) formation, tau aggregates and forms tau oligomer and granular tau oligomer. Hyperphosphorylated tau and tau oligomers are involved in synapse loss, and granular tau oligomer causes neuronal loss. Blocking granular tau oligomer formation results in inhibition of neuronal loss accompanying ameliorated neuronal dysfunction in a mouse model.
See this image and copyright information in PMC

References

    1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. - PubMed
    1. Rosenblum W.I. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging. 2014;35:969–974. - PubMed
    1. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925–931. - PubMed
    1. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17–24. - PubMed
    1. Goedert M., Spillantini M.G. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. Biochim Biophys Acta. 2000;1502:110–121. - PubMed